Navigation Links
Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
Date:8/19/2007

hibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is being tested in combination with bortezomib (Velcade(R)) in patients with multiple myeloma in a registration program called TIME. Tanespimycin is also being studied in multiple myeloma as monotherapy, in HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab), and as monotherapy in metastatic melanoma. Intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials in hematologic cancers and in HER2-positive metastatic breast cancer.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD).

For additional information on Kosan Biosciences, please visit the company's website at http://www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements relating to the potential for Kosan to receive milestone payments and royalties from the license agreement with Pfizer; the further development and potential safety, efficacy and commercialization of Kosan's product candidates, including without limitation PF-04548023 and other compounds from Kosan's motilin agonist program; and development plans with respect to PF-04548023 and the timing thereof. There are a number of
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
5. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
6. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
7. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014 /PRNewswire-iReach/ -- "Fatty Liver Disease Global ... Fatty Liver Disease clinical trial scenario. This report provides ... trials on Fatty Liver Disease . It includes an ... as per the site of trial conduction across the ... clinical trials by their phase, trial status, prominence of ...
(Date:8/27/2014)... WARSAW, Ind. , Aug. 27, 2014  Zimmer ... in musculoskeletal care, announced that it will be participating ... the Grand Hyatt in New York, New ... David Dvorak , President and CEO of Zimmer, will ... Binder , President and CEO of Biomet, will join ...
(Date:8/27/2014)... LONDON , Aug. 27, 2014  As ... is pleased to announce the addition of new ... Center. The Medical Devices Knowledge Center ... research in the healthcare industry. Users have access ... expert, Kalorama Information, published from 1998 to present ...
Breaking Medicine Technology:Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 2MarketResearch.com: New Medical Devices Research Reports Added to Kalorama Information Knowledge Center 3
... RDEA594 Data to Be Presented at the 2008 Annual European Congress of, Rheumatology ... Phase 1 Human Study of RDEA594 Planned in Second Half of ... ... Biosciences, Inc.,(Nasdaq: RDEA ) today announced the identification of its lead development,candidate ...
... filing anticipated in 1Q 2009 -, PRINCETON, ... ) has nominated PSI-7851 as a lead development ... (HCV). PSI-7851 is a proprietary,nucleotide analogue polymerase inhibitor ... Practice (GLP) animal toxicity studies required for,submission of ...
Cached Medicine Technology:Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 2Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 3Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 4Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594 5Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 2Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C 3
(Date:8/27/2014)... 27, 2014 When a friend invited Misty Mozejko ... But it was the beginning of a new way of life ... unhappy,” says Misty. “I knew I needed to turn my life ... may have been, Misty stuck with the program. “It was so ... so out of my comfort zone, but between the boot camp ...
(Date:8/27/2014)... 2014 Hastings and Hastings, a firm ... local offices is pleased to report having saved a ... $150,000. Hastings and Hastings is a dedicated and focused ... everything from automobile accident cases to pedestrian cases and ... routinely works with slip and fall accident victims, motorcycle ...
(Date:8/27/2014)... Minneapolis, Minn. (PRWEB) August 27, 2014 ... law and policy will gather at the Minneapolis Marriott ... into the worldwide explosion of robotics and autonomous systems ... , In recognition of the wide variety of ... Alley Conference & Expo created nine different tracks of ...
(Date:8/27/2014)... StartX , a nonprofit technology accelerator ... a pioneering institute driving biotechnology innovation at the University ... laboratory customized for the needs of early stage medical ... lab space, named “StartX-QB3 Labs,” is the first research ... Care focused on developing entrepreneurs from academia to industry. ...
(Date:8/27/2014)... For the first time, a living ... surgery when triple-board certified, Park Avenue plastic surgeon Dr. ... he has created from life – and the faces ... a unique event on September 9, 2014 at prestigious ... Street. The “faces” who will be appearing in this ...
Breaking Medicine News(10 mins):Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 2Health News:Whitby Fit Body Boot Camp Releases Gift Certificate for Two-Week Complimentary Access to Fitness Boot Camp 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $6,500 On A Settlement Of $150,000 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $6,500 On A Settlement Of $150,000 3Health News:Robotics Alley, LifeScience Alley Partner on Health Care & Medical Device Track 2Health News:Robotics Alley, LifeScience Alley Partner on Health Care & Medical Device Track 3Health News:Robotics Alley, LifeScience Alley Partner on Health Care & Medical Device Track 4Health News:Robotics Alley, LifeScience Alley Partner on Health Care & Medical Device Track 5Health News:StartX & QB3 Launch Lab for Life Science and Medical Technology Entrepreneurs 2Health News:StartX & QB3 Launch Lab for Life Science and Medical Technology Entrepreneurs 3Health News:StartX & QB3 Launch Lab for Life Science and Medical Technology Entrepreneurs 4Health News:Presenting A Remarkable Fusion of Art, Fashion and Plastic Surgery 2
... ... strength and momentum in the business services sector. , ... Baltimore, Md. (PRWEB) November 24, 2009 -- Slate ... New Markets Venture Partners ( www.newmarketsvp.com ), a venture capital firm based in College ...
... Two ... - ban,- don: verb: to leave completely and finally; forsake utterly; to desert. ... Vancouver, Canada ... the second webinar is its groundbreaking "The New Paradigm for 21st Century Therapy" series ...
... ... impacted by acute sinusitis or chronic sinusitis, Sinus Dynamics non-invasive nasal ... types of Sinusitis without any limitation or interference associated with any ... nasal nebulized antibiotics with mean particle diameter of 3.2 µm had ...
... ... EyeCentral Remote Video Platform for the Security Industry to Generate Recurring Monthly Revenue for ... ... Remote Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central ...
... WASHINGTON, Nov. 24 New peer-reviewed data finding that fewer ... chronic hepatitis C virus have received anti-viral therapy in recent ... move urgently on bipartisan legislation to support new state-based detection, ... (NVHR) said today. , The NVHR warns ...
... Researchers from the University of Michigan determined that only ... C virus (HCV) infection received antiviral therapy between 2002 ... in part because only half of the patients know ... by 2030 less than 15% of liver-related deaths from ...
Cached Medicine News:Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 2Health News:Slate Capital Group and New Markets Venture Partners Acquire eCoast Sales Solutions 3Health News:Home For the Holidays: MyShrink.com Announces the Second in its Successful Six-Part Webinar Series: "Abandonment: The Hidden Fear" 2Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 2Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 3Health News:Sinusitis Treatment Using Nebulized Medications to Treat Sinusitis Rather than Sinus Surgery 4Health News:NCL Security Launches EyeCentral Video Platform for the Security Industry to Generate Recurring Monthly Revenue for Central Stations and Security Dealers 2Health News:NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington 2Health News:NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is 'Wake-Up Call' for Washington 3Health News:Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US 2
... Sunrise Technologies has developed laser thermal keratoplasty (LTK). ... 30, 2000 for the temporary reduction of hyperopia ... years and older with up to 0.75 diopters ... 6 months. Unlike most refractive surgery, LTK ...
... The OcuLight family of infrared laser ... SLx models. These diode lasers serve as ... devices and applications, require no regular maintenance ... with their compact design. The OcuLight SLx ...
... Danker Laboratories manufacturers ... RGP orthokeratology lenses (also ... or "Corneal Reshaping" Lenses) ... specifications and demanding standards ...
... contact lenses used for corneal refractive therapy, ... The patient wears the lenses overnight while ... the day, nearsightedness is corrected or greatly ... contact lenses apply slight pressure to the ...
Medicine Products: